AbbVie Inc. Stock Falls Wednesday, Still Outperforms Market

Gold Line Resources Ltd

Change company Symbol lookup

Select an option...

TLLZF Gold Line Resources Ltd

DWAC Digital World Acquisition Corp

TMP Tompkins Financial Corp

CCF Chase Corp

CHKP Check Point Software Technologies Ltd

GGXXF Ggx Gold Corp

ICE Intercontinental Exchange Inc

AICAF Air China Ltd

LGF.A Lions Gate Entertainment Corp

COMM CommScope Holding Company Inc

Based in Canada

Company profile

Gold Line Resources Ltd. is a Canada-based company. The Company’s principal business activity is the acquisition and exploration of mineral property interests, particularly in Sweden and Finland. It holds a portfolio of advanced and early stage gold exploration properties in Sweden and Finland, including the Oijarvi Project, which includes the Kylmakangas deposit, in the Oijarvi Greenstone Belt of Finland; the Solvik Gold Project, located in Sweden, the Kankberg Norra property in the Skelleftea Belt , and the Langtjarn property (comprised of the Stojuktan North and Storjuktan South licences), the Blabarliden property, and the Paubacken property, all located within the Gold Line Mineral Belt, in Sweden. The Langtjarn property is a 22,336-hectare license package located at the northern end of the Gold Line Mineral Belt of North Central Sweden. The Blabarliden property consists of a 3,806-hectare license package. The Paubacken property consist of 16,724-hectare licensed package.

AbbVie Inc. Stock Falls Wednesday, Still Outperforms Market

4:33 pm ET November 16, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of AbbVie Inc. (ABBV) slid 0.76% to $151.87 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.83% to 3,958.79 and Dow Jones Industrial Average falling 0.12% to 33,553.83. The stock's fall snapped a four-day winning streak. AbbVie Inc. closed $24.04 below its 52-week high ($175.91), which the company reached on April 8th.

The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Pfizer Inc. (PFE) fell 1.07% to $48.05, Eli Lilly & Co. (LLY) rose 0.85% to $352.93, and AstraZeneca PLC ADR (AZN.LN) fell 0.23% to $63.80. Trading volume (7.2 M) eclipsed its 50-day average volume of 5.7 M.

Data source: Dow Jones Market Data, FactSet. Data compiled November 16, 2022.

(END) Dow Jones Newswires

November 16, 2022 16:33 ET (21:33 GMT)